JGJaswinder Gill

Jaswinder Gill

*This is an algorithmically generated author record based on publicly available information.

Jaswinder Gill has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Convergent ablation for persistent atrial fibrillation: outcomes from a single-centre real-world experience

    by Nilanka N Mannakkara, Bradley Porter, Nicholas Child, Baldeep S Sidhu, Vishal S Mehta, Mark K Elliott, Justin Gould, Shahada Ahmed, Reza Razavi, Christopher A Rinaldi, et al.

    Atrial fibrillation (AF) is common and can cause significant morbidity and detriment to quality of life. Success rates for conventional catheter ablation are suboptimal in persistent AF (PsAF), especially when longstanding. Convergent hybrid ablation combines endoscopic surgical epicardial and endocardial catheter ablation. It offers promise in treating PsAF. We aimed to evaluate outcomes at our centre following convergent ablation. We conducted an observational study of patients undergoing ablation from 2012 to 2019 at a London cardiac centre. Sixty-seven patients underwent convergent ablation entailing epicardial ablation, mostly via sub-xiphoid access, followed by endocardial left atrial catheter ablation. Baseline and follow-up data were obtained retrospectively from clinical records. Primary outcome was freedom from AF on/off anti-arrhythmic drugs after 12-month follow-up. Secondary outcomes included freedom from AF over the entire follow-up, freedom from anti-arrhythmic drugs, freedom from atrial arrhythmias, symptom status, repeat ablation and complications. At baseline, 80.6% had PsAF >1 year (80.6%), 49.3% had body mass index >30 kg/m2 at baseline and 19.4% had left ventricular ejection fraction of 40% or less. The median follow-up was 2.3 (1.4–3.7) years. Freedom from AF recurrence was 81.3% at 1 year and 61.5% over overall follow-up. Eleven patients (16.4%) required redo AF ablation. Prolonged AF duration was associated with increased recurrence at 12 months and duration >5 years with a shorter time to recurrence on Kaplan–Meier analysis, but this and other factors did not significantly impact the AF recurrence during the overall follow-up period. Convergent ablation had good 1-year and overall success rates for treating PsAF. Our results in a diverse, real-world population support the potential of convergent ablation in patients with challenging to treat PsAF.


  • Open Access

    Assessing the ability of substrate mapping techniques to guide ventricular tachycardia ablation using computational modelling

    by Fernando O. Campos, Michele Orini, Robert Arnold, John Whitaker, Mark O'NEill, Reza Razavi, Gernot Plank, Ben Hanson, Bradley Porter, Christopher Aldo Rinaldi, et al.


  • Top Cited Papers

    Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation

    by David B. DeLurgio, Karl J. Crossen, Jaswinder Gill, Christopher Blauth, Saumil R. Oza, Anthony R. Magnano, Mark A. Mostovych, Michael E. Halkos, David R. Tschopp, Faraz Kerendi, et al.

    Background: The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a minimally invasive epicardial/endocardial ablation approach (Hybrid Convergent) to achieve a more comprehensive lesion set with durable transmural lesions. The multicenter randomized controlled CONVERGE trial (Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF) evaluated the safety of Hybrid Convergent and compared its effectiveness to CA for persistent and long-standing persistent AF treatment. Methods: One-hundred fifty-three patients were randomized 2:1 to Hybrid Convergent versus CA. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously failed/intolerant class I/III antiarrhythmic drugs through 12 months. Primary safety was major adverse events through 30 days. CONVERGE permitted left atrium size up to 6 cm and imposed no limits on AF duration, making it the only ablation trial to substantially include long-standing persistent–AF, that is, 42% patients with long-standing persistent–AF. Results: Of 149 evaluable patients at 12 months, primary effectiveness was achieved in 67.7% (67/99) patients with Hybrid Convergent and 50.0% (25/50) with CA ( P =0.036) on/off previously failed antiarrhythmic drugs and in 53.5% (53/99) versus 32.0% (16/50; P =0.0128) respectively off antiarrhythmic drugs. At 18 months using 7-day Holter, 74.0% (53/72) Hybrid Convergent and 55% (23/42) CA patients experienced ≥90% AF burden reduction. A total of 2.9% (3/102) patients had primary safety events within 7 days, and 4.9% (5/102) between 8 and 30 days postprocedure. No deaths, cardiac perforations, or atrioesophageal fistulas occurred. All but one primary safety event resolved. Conclusions: The Hybrid Convergent procedure has superior effectiveness compared to the CA for the treatment of persistent and long-standing persistent atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01984346.


  • Open Access

    Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE Trial): Rationale and design

    by David B. DeLurgio, Edward Ferguson, Jaswinder Gill, Christopher Blauth, Saumil Oza, Mark Mostovych, Yashasvi Awasthi, Nfii Ndikintum, Karl Crossen


  • Transvenous lead extraction in patients with cardiac resynchronization therapy devices is not associated with increased 30-day mortality

    by Justin Gould, Magdalena Klis, Bradley Porter, Benjamin J Sieniewicz, Baldeep S Sidhu, Simon Claridge, Steven E Williams, Anoop Shetty, Mark O’Neill, Jaswinder Gill, et al.

    Transvenous lead extraction (TLE) may be necessary due to system infection/erosion or lead malfunction. Cardiac resynchronization therapy (CRT) patients undergoing TLE may be at greater risk due to increased comorbidities. We examined whether patients with CRT systems undergoing TLE had more comorbidities and higher 30-day mortality than those with non-CRT devices. All TLEs between October 2000 and December 2016 were prospectively collected. During this period 925 TLEs occurred (CRT group 231, non-CRT group 694). Cardiac resynchronization therapy patients were older (68.1 ± 10.8 years vs. 64.3 ± 16.1 years, P = 0.024); more likely male (85.7% vs. 69%, P < 0.001); had lower mean left ventricular ejection fraction (34.1 ± 12.7% vs. 48.3 ± 12.9%, P < 0.001); had higher prevalence of renal impairment (33.8% vs. 13.7%, P < 0.001) and were more likely to have ≥2 comorbidities (84% vs. 40.1%, P < 0.001). Mean lead dwell time was lower in the CRT group (5.6 ± 5.5 years vs. 7.6 ± 7.1 years, P = 0.002). There was no significant difference in all-cause 30-day mortality rates between CRT (3.0%, n = 7) and non-CRT patients (2.0%, n = 14) (P = 0.443). The majority of deaths in both groups were due to sepsis. Univariate and multivariate analysis showed age, renal impairment and sepsis were associated with increased risk of 30-day mortality. Transvenous lead extraction of a CRT system did not predict 30-day mortality. Transvenous lead extraction in CRT patients was not associated with increased 30-day mortality when compared with non-CRT patients. Age, renal impairment and sepsis were independent predictors of 30-day mortality. Sepsis was the main cause of 30-day mortality.


  • Open Access

    Pulse Arrival Time Accurately Detects Pacing-Induced Mechanical Alternans

    by Stefan van Duijvenboden, Nick Child, Ben Hanson, Jaswinder Gill, Peter Taggart, Michele Orini


  • Open Access

    Autonomic Modulation in Patients with Heart Failure Increases Beat-to-Beat Variability of Ventricular Action Potential Duration

    by Bradley Porter, Martin J. Bishop, Simon Claridge, Jonathan Behar, Benjamin J. Sieniewicz, Jessica Webb, Justin Gould, Mark O'NEill, Christopher A. Rinaldi, Reza Razavi, et al.

    Background: Exaggerated beat-to-beat variability of ventricular action potential duration (APD) is linked to arrhythmogenesis. Sympathetic stimulation has been shown to increase QT interval variability, but its effect on ventricular APD in humans has not been determined. Methods and Results: 11 heart failure patients with implanted bi-ventricular pacing devices had activation–recovery intervals (ARI, surrogate for APD) recorded from LV epicardial electrodes under constant RV pacing. Sympathetic activity was increased using a standard autonomic challenge (Valsalva) and baroreceptor indices were applied to determine changes in sympathetic stimulation. Two Valsalvas were performed for each study and were repeated, both off and on bisoprolol. In addition sympathetic nerve activity (SNA) was measured from skin electrodes on the thorax using a novel validated method. Autonomic modulation significantly increased mean short-term variability in ARI; off bisoprolol mean STV increased from 3.73±1.3 ms to 5.27±1.04 ms (p=0.01), on bisoprolol mean STV of ARI increased from 4.15±1.14 ms to 4.62±1 ms (p=0.14). Adrenergic indices of the Valsalva demonstrated significantly reduced beta-adrenergic function when on bisoprolol (Δ pressure recovery time, p=0.04; Δ systolic overshoot in Phase IV, p=0.05). Corresponding increases in SNA from rest both off (1.4 uV, p<0.01) and on (0.7 uV, p<0.01) bisoprolol were also seen. Conclusions: Beat-to-beat variability of ventricular APD increases during brief periods of increased sympathetic activity in patients with heart failure. Bisoprolol reduces, but does not eliminate, these effects. This may be important in the genesis of ventricular arrhythmias in heart failure patients.


  • Open Access

    16-24: Identification of Heterogeneous Intra-Atrial Conduction Delay in Paroxysmal AF Patients by Dynamic Electrophysiological Characterization

    by Steven Williams, Nick Linton, James Harrison, Henry Chubb, John Whitaker, Radoslaw Kiedrowicz, Jaswinder Gill, Michael Cooklin, Christopher Aldo Rinaldi, Reza Razavi, et al.

    Purpose of the Study: Although atrial fibrillation (AF) is classified by arrhythmia duration, the presentation, clinical course and response to treatment vary widely within paroxysmal AF (PAF) patients. We hypothesized that variable electrical remodeling exists between PAF patients, resulting in intra-atrial conduction delay which could be identified using a novel programmed stimulation technique. Methods Used: In 15 PAF patients undergoing index PVI, high density LA contact mapping using a 20 pole Pentaray catheter was performed during pacing from two atrial sites (BCL 470ms, S1S2 350ms to atrial ERP in -2% steps). Regional atrial conduction delay (S1S2delay), activation dispersion, and AF vulnerability were measured. Computer modeling was used to interrogate the mechanism of conduction delay. Summary of Results: Conduction delay showed a bimodal distribution (peaks for HRA / CS pacing 275 ± 11 / 271 ± 11ms and 326 ± 13 / 319 ± 16ms) and patients with inducible AF were characterized by increased activation dispersion (ΔLAT 672 ± 41ms vs 542 ± 17ms, P = 0.0446, Fig). Action potential remodeling across the population could explain observed variation in conduction delay, but resulted in insufficient conduction velocity restitution variation (3.7 ± 0.5ms-1/s vs 2.3 ± 0.5 ms-1/s, P = 0.1926) to explain the activation dispersion seen in AF-inducible patients. Conclusions: Within the single clinical entity of PAF, programmed stimulation can identify a spectrum of activation patterns correlating with AF vulnerability. Rapid patient-specific conduction characterization may identify patients likely to respond to PVI alone for PAF.

  • Open Access

    16-26: Electrical Remodeling Does not Reproducibly Mirror Structural Change on Atrial MRI

    by Steven Williams, Henry Chubb, James Harrison, Nick Linton, John Whitaker, Radoslaw Kiedrowicz, Jaswinder Gill, Michael Cooklin, Christopher Aldo Rinaldi, Steven Niederer, et al.

    Purpose of the Study: Left atrial (LA) late gadolinium enhancement (LGE) CMR has been proposed to guide ablation therapy and predict procedure outcome. AF electrical and structural remodeling are known to occur to varying extents in patients with AF. The extent to which pre-procedural LGE CMR reflects LA electrophysiological remodeling is unknown. Methods Used: Intracardiac contact mapping during programmed stimulation was used to characterize conduction delay, activation dispersion, electrogram morphology and AF vulnerability in 8 patients undergoing first-time pulmonary vein isolation. Pre-procedural LGE CMR imaging was performed and quantified by LGE signal intensity (SI; image intensity ratio, IIR), % LGE area and LA sphericity indices. Summary of Results: Although electrogram voltage was significantly reduced at areas of high SI (IIR > 0.97 - 0.9mV vs 1.3mV P = 0.049), IIR showed no relationship with electrogram duration (17.7ms vs 18.3ms, P = 0.673), conduction delay (322ms vs 316ms, P = 0.3939) or conduction block (262ms vs. 262ms, P = 0.8667). There was no relationship between % LGE area or sphericity and any of the LA remodeling parameters (all P > 0.05). LA extrastimulus conduction curves showed significant variation between patients with similar LGE CMR findings (Figure). Conclusions: Although these results confirm that electrogram voltage may be significantly reduced at areas of high LGE signal intensity, other markers of LA remodeling showed significant variation between patients with similar LGE appearances. These findings may have important implications for patient-tailored ablation strategies guided by the integration of electrical and structural information.


  • Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort

    by Anthony S. Wierzbicki, Sania Nishtar, Peter J. Lumb, Michelle Lambert-Hammill, Martin A. Crook, Michael S. Marber, Jaswinder Gill